Список проголосовавших за комментарий " Aurinia Pharma target raised to $11 at FBR & Co. (8.37)FBR & Co. raises their AUPH tgt to $11 from $9 as they think that with a balance sheet bolstered by a public offering that we estimate raised up to $161M in net proceeds, AUPH is now in a strong position to independently advance voclosporin (VCS), its investigational therapy for patients with active lupus nephritis (LN), into Phase III testing. As VCS is directed to an autoimmune disease that has been targeted by major pharmaceutical companies (Big Pharma) hungry for the next multi-billion-dollar drug (FBR projects VCS could achieve >$2B in annual peak sales), <strong>firm looks for AUPH to receive an acquisition bid from a Big Pharma company in the next six to nine months, with an initial bid of $10 per share reasonable. They think AUPH is more likely to look to sign a partnership agreement; therefore, they look for a deal worth $500M to $700M in up-front and milestone payments to AUPH.</strong>"